Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

MasTec Q4 EPS $1.36 Beats $0.98 Estimate, Sales $3.01B Beat $2.91B Estimate

MasTec (NYSE:MTZ) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $0.98 by 38.78 percent. This is a 0.74 percent increase over earnings of $1.35 per share from the same period
byHappy Mohamed
February 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

MasTec (NYSE:MTZ) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $0.98 by 38.78 percent. This is a 0.74 percent increase over earnings of $1.35 per share from the same period last year. The company reported quarterly sales of $3.01 billion which beat the analyst consensus estimate of $2.91 billion by 3.38 percent. This is a 66.30 percent increase over sales of $1.81 billion the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca and Daiichi Sankyo Announced ENHERTU Met the Primary Endpoint of Progression-free Survival in Patients With Hr-positive Disease, Reducing the Risk of Disease Progression or Death by 49% Vs. Chemotherapy in Data Presented at ASCO

By Charles Gross
Today, 4:51 AM
Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated superior and clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) unresectable and/or metastatic breast c

AZN